It has been more than four years since the UK left the EU, but the government is still being forced to delay the introduction of border control rules that could have conse
The biopharma industry faces a relentless demand for evidence of real-world effectiveness (RWE), safety, and value throughout the product lifecycle to complement the clinical trial-based be
Moderna’s efforts to develop a range of mRNA vaccines for influenza have been bolstered with funding of up to $750 million from investment firm Blackstone Life Sciences.
Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling